Tsunami of patent losses in 2013. Top 15. The numbers.

We are in the midst of third quarter earnings reports, and they show with stark detail what the tsunami of patent losses means to the financial underpinning of drugmakers. It's a serious problem that will erode earnings for years to come. Pharmaceutical researcher EvaluatePharma estimates there are $290 billion of sales at risk from patent expirations between this year and 2018.

1 Cymbalta

2 Avonex

3 Humalog (!!!)

4 OxyContin

5 Rebif

6 Aciphex

7 Xeloda

8 Procrit

9 Neupogen

10 Zometa

11 Lidoderm

12 Temodar

13 Asacol

14 Niaspan

15 Reclast